In alignment with the TCGA patient survival data mentioned earlier, PCa patients with high levels of FOXA1 transcripts exhibited longer periods of biochemical recurrence-free survival, whereas those with elevated NR3C1 transcript levels experienced shorter survival intervals (Supplementary Figure S16H–J). The gene discussed is FOXA1; the disease is posterior cortical atrophy.